Ca-AKG

An ongoing randomized, double-blind, placebo-controlled clinical trial in generally healthy adults aged 45-75 years evaluating CaAKG supplementation for 12 weeks, with primary outcomes measuring biological aging via PhenoAge and secondary outcomes including physical performance, inflammatory markers, glucose and lipid metabolism, and quality of life.

A randomized controlled trial recruiting 120 middle-aged participants with elevated DNA methylation age compared to chronological age to test whether Ca-AKG supplementation can reduce biological age and improve muscle strength, cardiovascular function, and aerobic capacity over 9 months.

A clinical study of 42 healthy adults using TruAge DNA methylation testing found that Ca-AKG supplementation combined with gender-specific vitamins produced an average reduction of 7.96 years in biological age after approximately 7 months of use, with males experiencing an 8.44-year reduction and females a 6.98-year reduction.

Analysis of 42 self-reported healthy individuals taking Rejuvant (sustained-release Ca-AKG plus vitamins) for 4-10 months showed a statistically significant average reduction of 7.96 years in epigenetic age, from 0.35 years younger to 8.31 years younger than chronological age.

Preclinical research demonstrated that AKG-fed mice showed improved physical appearance, scored 40% better on frailty tests measuring 31 physiological attributes including hair color, hearing, gait, and grip strength, and female mice lived 8-20% longer than control mice.

A long-term real-world study found that sustained-release Ca-AKG at a dose similar to one NOVOS Core sachet was linked to a nearly 8-year reduction in biological age measured from DNA in saliva after several months of daily use.

A randomized controlled trial recruiting 120 middle-aged participants with elevated DNA methylation age compared to chronological age to test whether Ca-AKG supplementation can reduce biological age and improve muscle strength, cardiovascular function, and aerobic capacity over 9 months.

Preclinical research demonstrated that AKG-fed mice showed improved physical appearance, scored 40% better on frailty tests measuring 31 physiological attributes including hair color, hearing, gait, and grip strength, and female mice lived 8-20% longer than control mice.

Preclinical research demonstrated that AKG-fed mice showed improved physical appearance, scored 40% better on frailty tests measuring 31 physiological attributes including hair color, hearing, gait, and grip strength, and female mice lived 8-20% longer than control mice.

Analysis of 42 self-reported healthy individuals taking Rejuvant (sustained-release Ca-AKG plus vitamins) for 4-10 months showed a statistically significant average reduction of 7.96 years in epigenetic age, from 0.35 years younger to 8.31 years younger than chronological age.

A clinical study of 42 healthy adults using TruAge DNA methylation testing found that Ca-AKG supplementation combined with gender-specific vitamins produced an average reduction of 7.96 years in biological age after approximately 7 months of use, with males experiencing an 8.44-year reduction and females a 6.98-year reduction.

A randomized controlled trial recruiting 120 middle-aged participants with elevated DNA methylation age compared to chronological age to test whether Ca-AKG supplementation can reduce biological age and improve muscle strength, cardiovascular function, and aerobic capacity over 9 months.

An ongoing randomized, double-blind, placebo-controlled clinical trial in generally healthy adults aged 45-75 years evaluating CaAKG supplementation for 12 weeks, with primary outcomes measuring biological aging via PhenoAge and secondary outcomes including physical performance, inflammatory markers, glucose and lipid metabolism, and quality of life.

A randomized controlled trial recruiting 120 middle-aged participants with elevated DNA methylation age compared to chronological age to test whether Ca-AKG supplementation can reduce biological age and improve muscle strength, cardiovascular function, and aerobic capacity over 9 months.

A randomized controlled trial recruiting 120 middle-aged participants with elevated DNA methylation age compared to chronological age to test whether Ca-AKG supplementation can reduce biological age and improve muscle strength, cardiovascular function, and aerobic capacity over 9 months.

A clinical study of 42 healthy adults using TruAge DNA methylation testing found that Ca-AKG supplementation combined with gender-specific vitamins produced an average reduction of 7.96 years in biological age after approximately 7 months of use, with males experiencing an 8.44-year reduction and females a 6.98-year reduction.